Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023:72:3351-3355.
doi: 10.1016/j.matpr.2022.07.387. Epub 2022 Aug 2.

Interleukin 6: A biomarker for COVID-19 progression

Affiliations

Interleukin 6: A biomarker for COVID-19 progression

El-Houcine Sebbar et al. Mater Today Proc. 2023.

Abstract

COVID-19 was discovered in China for the first time in December 2019 and was declared a pandemic by the World Health Organization on March 11, 2020. Due to its rapid geographic expansion over the last three years, it has now become a global health issue. The infection is caused by SARS-CoV-2, which is obtained from a zoonotic source and transmitted directly or through contact. Following exposure, the immune system becomes hyperactive resulting in the production of pro-inflammatory cytokines, particularly interleukin-6 (IL-6), a naturally occurring pleiotropic cytokine that plays a significant role in respiratory failure and multi-organ dysfunction. This massive inflammatory phenomenon is reminiscent of cytokine release syndrome (CRS) or "cytokine storm", which may be at the root of many severe complications. In fact, serum IL-6 levels are significantly high in patients with severe Covid-19 disease. The goal of treatment is to change the cytokine's concentration or activity. Interleukin-6 production could be inhibited, reducing inflammation and so serving as a therapeutic target. anti-interleukin-6 receptor monoclonal antibodies have been proven to reduce the severity of COVID-19 in clinical trials aimed at clarifying the function of immunoregulation. As a result, the Il-6 assay is a reliable predictor of morbidity and mortality at the time of infection diagnosis. The aim of our study is to highlight the role of interleukin 6 as biomarker of the COVID- 19 progression.

Keywords: Biomarker; COVID-19; Cytokine storm; Interleukin-6; Monoclonal antibodies; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
In healthy state, the Angiotensin II –Angiotensin I Receptor axis and the Angiotensin 1–7-Mas receptor axis are in a state of dynamic equilibrium to maintain the blood pressure. The former causes an inflammatory response while the latter suppresses inflammatory responses. In SARS-CoV-2 infected state, viral binding to ACE2 renders it unavailable to bind to Angiotensin II causing an imbalance between the two axes and a shift towards the proinflammatory functions .

Similar articles

Cited by

References

    1. Zhu N.a., Zhang D., Wang W., Li X., Yang B.o., Song J., Zhao X., Huang B., Shi W., Lu R., Niu P., Zhan F., Ma X., Wang D., Xu W., Wu G., Gao G.F., Tan W. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 2020;382(8):727–733. - PMC - PubMed
    1. Wu Y., et al. SARS-CoV-2 is an appropriate name for the new coronavirus. Lancet. 2020;395(10228):949–950. - PMC - PubMed
    1. Wong G., Liu W., Liu Y., Zhou B., Bi Y., Gao G.F. MERS, SARS, and Ebola: the role of super-spreaders in infectious disease. Cell Host Microbe. 2015;18(4):398–401. - PMC - PubMed
    1. Zhou P., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273. - PMC - PubMed
    1. Guan W., et al. China medical treatment expert group for Covid-19. Clin. Charact. Coronavirus Dis. 2019;382(18):1708–1720. - PubMed

LinkOut - more resources